Literature DB >> 11668469

Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.

C C Dorvault1, K N Weilbaecher, H Yee, D E Fisher, L A Chiriboga, Y Xu, D C Chhieng.   

Abstract

BACKGROUND: The diagnosis of melanoma can be difficult because of shared cytomorphology with other malignant neoplasms. The most commonly used melanocytic markers, anti-S-100 protein and HMB-45 antigen, have limited specificity and sensitivity, respectively. Microphthalmia transcription factor (Mitf) is a nuclear transcription factor critical for the development and survival of melanocytes and has been shown as a sensitive and specific marker for melanoma in histologic specimens.
METHODS: To evaluate the efficacy of Mitf as a marker for melanoma in cytologic preparations, 81 cell blocks from 44 patients with melanoma and 37 patients with nonmelanoma malignancies (29 patients with carcinoma, 4 patients with mesotheliomas, 2 patients with lymphoma, and 2 patients with islet cell tumors) were stained with monoclonal antibodies against Mitf (clone D5), S-100 protein, and HMB-45 antigen. The staining was evaluated blindly by three independent observers. The presence of nuclear staining for Mitf and cytoplasmic staining for S-100 protein or HMB-45 antigen in > 10% of tumor cells was considered positive staining for each antigen.
RESULTS: Forty-four melanomas (100%), including all 3 spindle-cell melanomas, were positive for Mitf. All nonmelanoma neoplasms were negative with only one exception: One mammary carcinoma showed rare (< 10%), weak nuclear staining with Mitf. The sensitivity and specificity of Mitf as a marker for melanoma were both 100%, whereas the sensitivity of HMB-45 antigen was 90.4%, and the specificity of S-100 protein was 70.3%.
CONCLUSIONS: Mitf is a sensitive and specific marker for malignant melanoma, including the spindle-cell variant, in cytologic specimens and may be superior to the current standard melanocytic markers, S-100 protein and HMB-45 antigen. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668469     DOI: 10.1002/cncr.9049

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations.

Authors:  Grant E Nybakken; Michael Sargen; Ronnie Abraham; Paul J Zhang; Michael Ming; Xiaowei Xu
Journal:  Am J Dermatopathol       Date:  2013-02       Impact factor: 1.533

Review 2.  Regulation of melanocyte pivotal transcription factor MITF by some other transcription factors.

Authors:  Ping Wan; Yongqing Hu; Li He
Journal:  Mol Cell Biochem       Date:  2011-04-26       Impact factor: 3.396

3.  MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes.

Authors:  Hee-Young Park; Christina Wu; Laurie Yonemoto; Melissa Murphy-Smith; Heng Wu; Christina M Stachur; Barbara A Gilchrest
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

4.  Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF.

Authors:  Erez Feige; Satoru Yokoyama; Carmit Levy; Mehdi Khaled; Vivien Igras; Richard J Lin; Stephen Lee; Hans R Widlund; Scott R Granter; Andrew L Kung; David E Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

5.  Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes.

Authors:  Amir Sonnenblick; Carmit Levy; Ehud Razin
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 6.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

7.  Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3.

Authors:  Carmit Levy; Amir Sonnenblick; Ehud Razin
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.